Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a leading company in the field of immuno-dermatology, is set to participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston. The company's management will engage in a fireside chat on March 2 at 1:50 p.m. ET, which will be available via a webcast on their website for 180 days.
Arcutis is renowned for its commitment to developing innovative treatments for patients with immune-mediated dermatological conditions. The company boasts a portfolio of advanced topical treatments approved for three major inflammatory skin diseases. Their expertise in dermatology development has fostered a strong pipeline targeting various inflammatory dermatological conditions.
Despite a recent decrease in stock price, H.C. Wainwright maintained its "Buy" rating for Arcutis on February 26, 2026, when the stock was priced at $27.01. Currently, ARQT is priced at $26.97, reflecting a decrease of 5.60% with a change of $1.60. The stock has fluctuated between a low of $26.60 and a high of $28.15 today.
Over the past year, ARQT has reached a high of $31.77 and a low of $11.86. The company's market capitalization is approximately $3.3 billion, indicating its size and value in the market. The trading volume for ARQT on the NASDAQ exchange is 2,129,839 shares, showing active investor interest.
The press release also includes forward-looking statements, highlighting potential risks and uncertainties that could impact the company's future performance. These risks are detailed in the "Risk Factors" section of their Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2026. Arcutis emphasizes that these statements are based on current expectations and are subject to change.
